- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
- Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
- Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
- Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
- Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
More ▼
Key statistics
As of last trade Candel Therapeutics Inc (CADL:NMQ) traded at 8.79, -38.57% below its 52-week high of 14.30, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.41 |
---|---|
High | 9.05 |
Low | 8.33 |
Bid | 8.78 |
Offer | 8.81 |
Previous close | 8.55 |
Average volume | 1.49m |
---|---|
Shares outstanding | 29.74m |
Free float | 20.01m |
P/E (TTM) | -- |
Market cap | 254.32m USD |
EPS (TTM) | -1.29 USD |
Data delayed at least 15 minutes, as of May 29 2024 14:58 BST.
More ▼